USA-based biotech giant Amgen (Nasdaq: AMGN) has reported second-quarter 2016 financial results which beat forecasts, posting a profit of $1.87 billion, a year-on-year rise of 13%.
The company reported revenue of $5.69 billion, up 5.9% in the reporting period, also exceeding the $5.6 billion of six analysts surveyed by Zacks Investment Research.
Amgen said earnings per share (EPS) on a generally-accepted accounting principles GAPP) basis were $2.47 for the quarter. Earnings, adjusted for non-recurring costs, were $2.84 per share. The results topped the average estimate of 11 analysts surveyed by Zacks was for earnings of $2.74 per share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze